A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
R-Pharm
Seagen Inc.
Pfizer
Eli Lilly and Company
Pfizer
Bristol-Myers Squibb
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Novartis
Arcus Biosciences, Inc.
Jonsson Comprehensive Cancer Center
EMD Serono
Pfizer
Astellas Pharma Inc
AstraZeneca
University of Miami
City of Hope Medical Center
GlaxoSmithKline
Mayo Clinic
City of Hope Medical Center
Massachusetts General Hospital
Enliven Therapeutics
Massachusetts General Hospital
University of Alabama at Birmingham
Toray Industries, Inc
City of Hope Medical Center
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ipsen
IGM Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
Ono Pharmaceutical Co., Ltd.
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
University of Nebraska
Canadian Cancer Trials Group
Wake Forest University Health Sciences
University of Chicago
Barbara Ann Karmanos Cancer Institute